Paper
Dalton Transactions
3
MgSO4. The solvent was removed in vacuo to give an orange d, J = 8.8 Hz, stopper ArH), 6.39 (8H, m, hydroquinone ArH),
solid, which was purified using preparatory thin layer chromato- 5.05 (4H, s, –OCH2 axle), 4.75 (2H, s, FcH), 4.33 (2H, s, FcH),
3
graphy to give the desired [2]rotaxane as an orange solid.
4.25 (4H, t, J = 6.7 Hz, –CH2-triazole axle), 4.00 (5H, s, FcH),
tert-Butyl-functionalised, bis-prototriazole rotaxane (1a). 3.95–3.98 (8H, m, –CH2O macrocycle), 3.72–3.74 (8H, m,
3
Using tert-butyl isophthalic acid (18.8 mg, 0.085 mmol), –CONHCH2 macrocycle), 3.26 (4H, t, J = 6.7 Hz, –CH2NHCO),
t
oxalyl chloride (0.022 mL, 0.26 mmol), axle 10a (124 mg, 2.06 (4H, t, 3J = 6.8 Hz, –CH2CH2CH2 axle), 1.27 (54H, s, Bu
0.085 mmol), bisamine 6 (60 mg, 0.085 mmol) and triethyl- axle); 13C-NMR (125 MHz, CDCl3–d4-MeOD 1 : 1) δ 169.1, 166.9,
amine (0.047 mL, 0.34 mmol) yielded 1a (32 mg, 16%). 1H 163.1, 157.0, 153.7, 153.5, 152.1, 149.2, 145.0, 145.0 (repeat),
NMR (500 MHz, CDCl3–d4-MeOD 1 : 1) δ 8.44 (2H, s, pyridine 124.4, 141.3, 140.4, 135.3, 134.7, 133.6, 133.2, 131.6, 130.5,
t
N-oxide ArH), 8.42 (1H, s, Fc-ArH), 8.39 (1H, s, Bu-ArH), 8.11 128.9, 126.6, 124.9, 124.7, 123.6, 116.0, 114.1, 83.9, 70.6, 70.6
(2H, s, Fc-ArH), 8.10 (1H, s, pyridine N-oxide ArH), 8.10 (2H, s, (repeat), 67.6, 67.5, 64.0, 62.3, 50.0, 40.9, 38.1, 35.0, 32.1, 32.0,
tBu-ArH), 7.82 (2H, s, triazoleH), 7.20 (12H, d, 3J = 8.3 Hz, 30.6, 29.6; MS (ESI +ve) m/z 2292.0956 ([M
+
Na]+,
3
stopper-ArH), 7.05 (16H, m, stopper ArH), 6.80 (4H, d, J = 8.8
Hz, stopper ArH), 6.37 (8H, s, hydroquinone ArH), 5.06 (4H, s,
C
138H152FeN14NaO13, calc. 2292.0905).
Nitro-functionalised, bis-prototriazole rotaxane (1d). 5-Nitro
–OCH2 axle), 4.84 (2H, br. s, FcH), 4.41 (2H, br. s, FcH), 4.21 isophthalic acid (15 mg, 0.070 mmol), oxalyl chloride
3
(4H, t, J = 6.5 Hz, –CH2-triazole axle), 4.10 (5H, s, FcH), 3.97 (0.018 mL, 0.21 mmol), axle 10a (100 mg, 0.070 mmol), bis-
(8H, m, –CH2O macrocycle), 3.73 (8H, m, –CONHCH2 macro- amine 6 (49 mg, 0.070 mmol) and triethylamine (0.040 mL,
1
cycle), 3.26 (4H, t, 3J = 6.5 Hz, –CH2NHCO axle), 2.04 (4H, t, 0.28 mmol) gave 1d (32 mg, 20%). H-NMR (500 MHz, CDCl3–
3J = 6.5 Hz, –CH2CH2CH2 axle), 1.34 (9H, s, tBu macrocycle), 1.27 d4-MeOD 1 : 1) δ 8.97 (1H, s, NO2-ArH), 8.88 (2H, s, NO2-ArH),
t
(54H, s, Bu axle); 13C NMR (125 MHz, CDCl3–d4-MeOD 1 : 1) δ 8.45 (2H, s, pyridine N-oxide ArH), 8.37 (1H, s, Fc-ArH), 8.14
169.1, 168.7, 162.7, 156.6, 153.2, 148.9, 144.7, 142.0, 140.9, (2H, s, Fc-ArH), 8.08 (1H, s, pyridine N-oxide ArH), 7.78 (2H, s,
3
140.0, 134.7, 134.4, 133.1, 132.9, 131.2, 128.9, 128.7, 124.6, triazoleH), 7.19 (12H, d, J = 8.5 Hz, stopper-ArH), 7.05 (16H,
123.1, 115.5, 113.7, 67.1, 63.6, 62.0, 40.8, 37.7, 35.6, 34.8, 31.7, m, stopper ArH), 6.79 (4H, d, 3J = 8.8 Hz, stopper ArH),
31.5, 30.4, 30.2; MS (ESI +ve) m/z 2348.1594 ([M + Na]+, 6.41–6.37 (8H, m, hydroquinone ArH), 5.04 (4H, s, –OCH2
3
C143H161FeN13NaO13, calc. 2348.1613).
axle), 4.74 (2H, s, FcH), 4.33 (2H, s, FcH), 4.25 (4H, t, J = 6.5
Bis-ferrocene functionalised bis-prototriazole rotaxane Hz, –CH2-triazole axle), 4.00 (5H, s, FcH), 3.99 (8H, m, –CH2O
(1b). 5-Ferrocene isophthalic acid (20 mg, 0.057 mmol), oxalyl macrocycle), 3.74 (8H, m, –CONHCH2 macrocycle), 3.26 (4H, t,
3
chloride (0.015 mL, 0.171 mmol), axle 10a (81 mg, 3J = 6.5 Hz, –CH2NHCO), 2.06 (4H, t, J = 6.5 Hz, –CH2CH2CH2
t
0.057 mmol), bisamine 6 (40 mg, 0.057 mmol) and triethyl- axle), 1.26 (54H, s, Bu axle); 13C-NMR (125 MHz, CDCl3–d4-
1
amine (0.032 mL, 0.23 mmol) gave 1b (30 mg, 22%). H NMR MeOD 1 : 1) δ 168.9, 166.5, 162.9, 156.7, 153.5, 153.3, 149.4,
(500 MHz, CDCl3–d4-MeOD 1 : 1) δ 8.41 (2H, s, pyridine 149.0, 144.8, 144.8 (repeated), 142.4, 141.1, 140.2, 136.8,
N-oxide ArH), 8.37 (2H, s, Fc-isophthalamide ArH), 8.14 (4H, s, 135.1, 133.4, 133.0, 131.9, 131.4, 128.7, 126.4, 126.2, 124.7,
Fc-isophthalamide ArH), 8.06 (1H, s, pyridine N-oxide ArH), 124.5, 123.3, 116.2, 115.8, 115.7, 113.8, 83.7, 70.4, 70.3,
3
7.72 (2H, s, triazoleH), 7.19 (12H, d, J = 8.5 Hz, stopper-ArH), 67.3, 63.7, 62.0, 40.9, 40.8, 37.9, 34.8, 31.8, 30.4, 29.4; MS
7.05 (16H, m, stopper ArH), 6.79 (4H, d, 3J = 8.8 Hz, stopper (ESI +ve) m/z 2336.0797 ([M + Na]+, C139H152FeN14NaO15, calc.
ArH), 6.37 (8H, s, hydroquinone ArH), 5.03 (4H, s, –OCH2 axle), 2336.0803).
4.75 (4H, s, FcH), 4.33 (4H, s, FcH), 4.20 (4H, t, 3J = 6.5 Hz,
tert-Butyl-functionalised, bis-iodotriazole rotaxane (1e). tert-
–CH2-triazole axle), 4.01 (10H, s, FcH), 3.97 (8H, m, –CH2O Butyl isophthalic acid (19 mg, 0.085 mmol), oxalyl chloride
macrocycle), 3.74 (8H, m, –CONHCH2 macrocycle), 3.25 (4H, t, (0.022 mL, 0.26 mmol), axle 10b (143 mg, 0.085 mmol), bis-
3
3J = 6.5 Hz, –CH2NHCO), 2.04 (4H, t, J = 6.5 Hz, –CH2CH2CH2 amine 6 (60 mg, 0.085 mmol) and triethylamine (0.047 mL,
t
1
axle), 1.26 (54H, s, Bu axle); 13C NMR (125 MHz, CDCl3–d4- 0.34 mmol) gave 13 (13 mg, 6%). H-NMR (500 MHz, CDCl3–
MeOD 1 : 1) δ 168.7, 162.7, 156.6, 153.2, 148.9, 144.7, 142.0, d4-MeOD 1 : 1) δ 8.48 (2H, s, pyridine N-oxide ArH), 8.38 (1H, s,
141.0, 140.0, 134.9, 133.1, 132.9, 131.3, 128.8, 124.6, 124.2, Fc-ArH), 8.37 (1H, s, Bu-ArH), 8.15 (2H, s, Fc-ArH), 8.14 (1H, s,
t
t
3
123.0, 115.6, 113.7, 83.6, 70.3, 67.3, 63.6, 62.0, 48.5, 40.8, 37.8, pyridine N-oxide ArH), 8.13 (2H, s, Bu-ArH), 7.20 (12H, d, J =
34.8, 31.8, 30.4; MS (ESI +ve) m/z 2475.0965 ([M + Na]+, 8.6 Hz, stopper-ArH), 7.07–7.04 (16H, m, stopper ArH), 6.81
3
C
149H161Fe2N13NaO13, calc. 2475.0928).
(4H, d, J = 8.9 Hz, stopper ArH), 6.40 (8H, m, hydroquinone
Pyridine-functionalised, bis-prototriazole rotaxane (1c). 3,5- ArH), 4.92 (4H, s, –OCH2 axle), 4.76 (2H, s, FcH), 4.37 (2H, s,
3
Pyridine dicarboxylic acid (12 mg, 0.070 mmol), oxalyl chloride FcH), 4.21 (4H, t, J = 7.0 Hz, –CH2-triazole axle), 4.00 (5H, s,
(0.018 mL, 0.21 mmol), axle 10a (100 mg, 0.070 mmol), bis- FcH), 3.97 (8H, m, –CH2O macrocycle), 3.73 (8H, m,
amine 6 (49 mg, 0.070 mmol) and triethylamine (0.040 mL, –CONHCH2 macrocycle), 3.29 (4H, t, 3J = 6.9 Hz, –CH2NHCO
1
3
0.28 mmol) gave 1c (14 mg, 9%). H-NMR (500 MHz, CDCl3– axle), 2.04 (4H, t, J = 6.9 Hz, –CH2CH2CH2 axle), 1.35 (9H, s,
d4-MeOD 1 : 1) δ 9.15 (2H, s, macrocycle pyridine ArH), 8.96 tBu macrocycle), 1.27 (54H, s, Bu axle); 13C-NMR (125 MHz,
t
(1H, s, macrocycle pyridine ArH), 8.45 (2H, s, axle pyridine CDCl3–d4-MeOD 1 : 1) δ 169.3, 168.9, 163.0, 156.9, 153.4, 153.3,
N-oxide ArH), 8.36 (1H, s, Fc-ArH), 8.13 (2H, s, Fc-ArH), 8.07 (1H, 149.1, 148.2, 144.9, 142.2, 141.2, 140.3, 135.1, 134.7, 133.5,
s, pyridine N-oxide ArH), 7.80 (2H, s, triazole-H), 7.19 (12H, d, 133.0, 131.4, 129.0, 128.8, 126.8, 124.8, 123.6, 123.5, 115.8,
3J = 8.5 Hz, stopper-ArH), 7.05 (16H, m, stopper ArH), 6.79 (4H, 114.1, 83.7, 83.0, 70.5, 70.4, 67.5, 67.5 (repeat), 67.4, 63.8, 62.1,
17276 | Dalton Trans., 2014, 43, 17274–17282
This journal is © The Royal Society of Chemistry 2014